Stock Detail
SHIRE PLC - AMERICAN DEPOSITARY SHARES EACH REPRESENTING THREE ORDINARY SHARES
Drug Manufacturers Other
SHPGY @ Yahoo Finance | SHPGY Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $96.43 | $97.60 | $-0.78 | -0.80% | 0.65 | $97.21 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $96.27 | $95.97 | 496,957 | 18.08B | 482,652.5 | 23.65 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 98.30 | 97.37 | 96.67 | 95.74 | 95.04 |
Stock Profile
Shire plc, a specialty pharmaceutical company, engages in the development and marketing of products in the areas of central nervous system, gastrointestinal, renal diseases, and human genetic therapies. The company's product portfolio includes ADDERALL and ADDERALL XR for attention deficit hyperactivity disorder; ADEPT for reduction of adhesions following abdominal surgery; AGRYLIN for the treatment of essential thrombocythaemia; CALCICHEW range used in the treatment and prevention of osteoporosis; CARBATROL, indicated for the treatment of epilepsy; DYNEPO for the treatment of anaemia in patients with chronic renal failure; EQUETRO used for the treatment of acute manic and mixed episodes associated with bipolar 1 disorder; and FOSRENOL, indicated to reduce serum phosphate in patients with end-stage renal disease. It also markets PENTASA for the treatment of patients with mild to moderately active ulcerative colitis; PROAMATINE for the treatment of symptomatic orthostatic hypotension; REMINYL XL for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type; REPLAGAL, which is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease; SOLARAZE for the treatment of actinic keratosis; 3TC tablets for the treatment of HIV infection; VANIQA used to treat facial hirsutism in women; XAGRID used for the reduction of elevated platelet counts in at-risk essential thrombocythaemia patients; and ZEFFIX, indicated for the treatment of chronic hepatitis B infection. It markets its products through distributors in the United States, Canada, the United Kingdom, Ireland, Germany, France, Spain, Italy, and Singapore. Shire plc was founded by Dennis Stephens, Harry Stratford, Peter Moriarty, and Geoff Hall in 1986. The company was formerly known as Shire Pharmaceuticals Group plc and changed its name to Shire plc in November 2005. Shire plc is headquartered in Basingstoke, the United Kingdom.